Rhythm Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Rhythm Pharmaceuticals reports significant revenue growth and pipeline advancements in its 2025 annual filing, despite continued operating losses, driven by IMCIVREE sales and promising clinical data.
NASDAQ
10-K: Rhythm Pharmaceuticals Reports Full Year 2024 Results, Highlights Progress in MC4R Pathway Programs
Rhythm Pharmaceuticals' 2024 10-K filing highlights the company's focus on rare neuroendocrine diseases and the advancement of its MC4R agonists, including IMCIVREE, with topline data from the Phase 3 trial in acquired hypothalamic obesity expected in the second quarter of 2025.
NASDAQ
Rhythm Pharmaceuticals' 2023 annual report highlights commercial growth of IMCIVREE, progress in clinical trials, and expansion of their pipeline with new drug candidates.